AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Avalo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.59+0.32 (+2.84%)
Close on Oct 19, 2026
- Market cap
- $505.35M
- P/E (TTM)
- –
- Dividend yield
- –
Avalo Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q4 25 | Q3 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $59.00K | $0 | – | $192.00K | $249.00K | $0 | $0 | $55.00K | $236.00K | $643.00K | $475.00K | $726.00K | 100.0% | -69.3% |
| License revenue | – | – | $0 | – | – | – | $0 | $516.00K | $0 | – | – | $170.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Avalo Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.